
CNBC Daily Open: The silver lining of positive earnings could be too blinding
Even a report that Trump wanted a minimum of 15%-20% tariffs on the European Union only dealt a minimal blow to markets, which mostly closed unchanged Friday. Although those figures are higher than the universal 10% baseline tariff Trump reportedly wanted — and which the EU is hoping to secure — they are still lower than the 30% Trump said he will impose on the bloc in his July 12 letter.
An upbeat start to earnings season has alsohelped to quell tariff fears for now. Around 83% of the S&P 500 companies that have reported earnings have exceeded expectations, according to FactSet data. In particular, big banks such as JPMorgan Chase and Goldman Sachs, which serve as barometers for economic activity, had solid beats, boosting investor sentiment.
Next in the spotlight are Big Tech earnings, which will be released in the weeks right before Aug. 1.If better than expected, they might dispel geopolitical jitters — or cause investors to dismiss trade fears too readily. In these stormy times, every silver lining has a dark cloud.
Aug. 1 is a 'hard deadline' for new tariffs. U.S. Commerce Secretary Howard Lutnick said Sunday that the tariffs will take effect next month, but left open the possibility of continuing trade negotiations after the date.
U.S. stock futures are little changed Sunday stateside. On Friday, the S&P 500 and Nasdaq Composite closed around the flatline. The Dow Jones Industrial Average, however, lost 0.32%. Asia-Pacific markets traded mixed Monday.
China keeps its benchmark lending rates steady. On Monday, the People's Bank of China announced it was holding the 1-year loan prime rate at 3.0% and the 5-year LPR at 3.5%. After the move, the offshore yuan remained mostly flat.
Huawei has evolved from a telecom giant to artificial intelligence leader. Despite — or precisely because of — restrictions imposed on the Chinese company by the U.S. in 2019, Huawei has achieved breakthroughs in its chips and appears to be Beijing's answer to Nvidia.
[PRO] The beneficiary of a foldable phone from Apple. While the Cupertino-based company has yet to release a foldable — unlike its rivals such as South Korea's Samsung and China's Honor — buyers are already lining up for a potential major supplier.
Singapore dollar exhibits safe-haven currency features. But it's no yen or Swiss franc — yet
While the greenback remains the world's reserve currency of choice, the dollar index has fallen over 9% year to date. The outlook for the Japanese yen has been clouded by trade worries.
Against such a backdrop, analysts suggest there could be an alternative safe-haven currency in the making: the Singapore dollar.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
China's Appetite for Nvidia H20 AI Chips Expands
Demand for Nvidia's H20 AI chips is so strong in China that Nvidia is looking beyond its existing inventory and ordering hundreds of thousands more from foundry TSMC. Reuters noted Monday that Nvidia's inventory could be as high as 700,000. The move to buy more chips emphasizes China's appetite for American AI hardware, even with less power than chips in the US. Nvidia developed the H20 to compete with Huawei, a chipmaker based in China. The US bars companies from selling US technology to Huawei. That approach appears to have been successful at slowing Huawei's progress in developing critical technology, but also makes it hard for China to turn anywhere else for chips. Nvidia has warned that software developers could switch to Huawei chips if they don't have access to Nvidia's chips and software tools. The H20 is much slower than Nvidia's H100 and H200 AI chips, which are available to customers outside China. Last year, Elon Musk used 100,000 H100 chips to create an impressive training cluster for xAI's Grok. Credit: Nvidia As NPR noted, the H20's fate was uncertain earlier this year, when it appeared the Trump administration was considering whether to ban or limit sales to China, the only major market for the slower chip. The administration later decided not to add restrictions to the H20, allowing Nvidia to sell its chip in China. The move is a boon both for Nvidia, which designed the chip, and for Taiwan-based TSMC, which manufactures the H20 for Nvidia. While Nvidia sold an estimated 1 million H20s in 2024, it could be on track to sell more this year. The company is believed to already have as much as 700,000 in inventory and has placed an order with TSMC for another 300,000. According to Reuters, Nvidia CEO Jensen Huang had indicated earlier that Nvidia would order more chips if the demand was there, and apparently, it is. China represents an important market for Nvidia, but the US has attempted to prevent the country from getting cutting-edge technology, wary of China's military. On top of those concerns, the US and China have been tangled in a trade war. Semiconductors largely avoided tariffs that affected many other products initially, but tariffs have fluctuated, and uncertainty has caused headaches for many US companies that do business with China.
Yahoo
10 minutes ago
- Yahoo
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase. The company reported earnings per American Depositary Share (EPADS) of 52 cents, surpassing analyst expectations of 47 cents. However, in yen terms, earnings per share (EPS) experienced a 14.1% decline, or a 10% decrease when adjusted for constant currency, reaching 151 yen. Total sales for the quarter amounted to $7.66 billion (1.11 trillion yen), exceeding consensus estimates of $7.53 billion. Despite this positive top-line performance, Takeda faced challenges on the bottom line, with core net profit dropping by 14.4% (or 10.3% at constant currency) to 237 billion key factor behind this decline was the significant erosion of revenue from Vyvanse, its attention-deficit hyperactivity disorder (ADHD) treatment, following the introduction of generic competition. This decline was anticipated by the company and was a major contributor to both the revenue drop and a reduction in core operating profit. View more earnings on TAK U.S. sales of Vyvanse fell 53.8% at constant exchange rates, dropping to 57.9 billion yen. The generics' market entry led to an overall sales decline of 46.9% for the drug during the quarter. On a more positive note, Takeda's portfolio of rare disease treatments showed resilience. Sales of Takhzyro, a treatment for hereditary angioedema, rose by 3.7% to 55.1 billion yen. Immunoglobulin sales also saw growth, increasing 2% at constant currency to 194 billion yen, while Albumin sales surged 16.2%, reaching 32.2 billion yen. In the vaccine segment, Takeda's Qdenga dengue vaccine experienced a 4.8% decline in sales at constant currency, amounting to 8.8 billion yen. However, the oncology division performed solidly, with Adcetris sales climbing 13.2% to 37.2 billion yen, while Fruzaqla, a novel therapy for certain cancers, saw a more modest growth of 8.9%, reaching 12.3 billion yen. Takeda's operating profit for the quarter rose 11% to 184.6 billion yen, while core operating profit dropped 15.8% (down 11.9% on a constant currency basis) to 321.8 billion yen. This decrease was primarily due to lower year-over-year impairment and restructuring expenses. Milano Furuta, Takeda's CFO, commented on the results, noting, 'The impact of Vyvanse generic erosion on Takeda's FY2025 Q1 results was very significant, but consistent with our expectations, and there is no change to our full-year outlook announced in May.' Outlook Takeda reaffirms its fiscal 2025 guidance, with core revenue of 4.53 trillion yen and core operating profit broadly flat at 1.14 trillion yen, and core earnings of 485 yen. Price Action: TAK stock is trading lower by 4.99% to $13.61 at last check Wednesday. Read Next:Photo by Veroniksha via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
10 minutes ago
- Yahoo
How major US stock indexes fared Wednesday, 7/30/2025
U.S. stock indexes slipped as doubts rise about whether the Federal Reserve will deliver economy-juicing cuts to interest rates by September. The S&P 500 fell 0.1% Wednesday. The Dow Jones Industrial Average dropped 0.4%, and the Nasdaq composite edged up 0.1%. Stocks felt pressure from rising Treasury yields after the Fed voted to hold its main interest rate steady. The move may upset President Donald Trump, who has been angrily lobbying for lower interest rates, but it was widely expected. What may have surprised investors even more was Fed Chair Jerome Powell's pushing back on expectations for a September cut. On Wednesday: The S&P 500 fell 7.96 points, or 0.1%, to 6,362.90. The Dow Jones Industrial Average fell 171.71 points, or 0.4%, to 44,461.28. The Nasdaq composite rose 31.38 points, or 0.1%, to 21,129.67. The Russell 2000 index of smaller companies fell 10.57 points, or 0.5%, to 2,232.40. For the week: The S&P 500 is down 25.74 points, or 0.4%. The Dow is down 440.64 points, or 1%. The Nasdaq is up 21.36 points, or 0.1%. The Russell 2000 is down 28.67 points, or 1.3%. For the year: The S&P 500 is up 481.27 points, or 8.2%. The Dow is up 1,917.06 points, or 4.5%. The Nasdaq is up 1,818.88 points, or 9.4%. The Russell 2000 is up 2.24 points, or 0.1%. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data